Nov 27, 2024
Artificial Intelligence (AI) is revolutionizing numerous fields, and healthcare, particularly cancer diagnostics, is no exception. With the promise of faster, more accurate diagnoses, AI is transforming how clinicians detect, diagnose, and treat cancer. By leveraging vast amounts of medical data, advanced algorithm...
Read More...
Nov 26, 2024
Ractigen Therapeutics Receives FDA Orphan Drug Designation for RAG-21 to Treat ALS Ractigen Therapeutics has announced that the FDA has granted Orphan Drug Designation (ODD) to RAG-21, its novel siRNA therapy for treating amyotrophic lateral sclerosis (ALS). RAG-21 specifically targets FUS-ALS, one of the most a...
Read More...
Nov 25, 2024
Cell and gene therapies are transforming Parkinson's treatment, bringing new hope to patients who previously had few options. While traditional approaches focus on symptom management, these advanced therapies target the underlying causes of the disease. By introducing healthy cells or repairing faulty genes, resear...
Read More...
Nov 21, 2024
Cartessa Aesthetics Partnered With Classys, Inc. to Bring Everesse to the US Market On November 14, 2024, Cartessa Aesthetics, a leading North American aesthetic medical device company, collaborated with Classys, Inc., a prominent global aesthetics firm based in South Korea, to introduce EVERESSE by Volnew...
Read More...
Nov 19, 2024
The Society for Immunotherapy of Cancer i.e., SITC 2024 conference provided a comprehensive view into the latest innovations in cancer immunotherapy, including data on CAR T-cell therapies, cancer vaccines, bispecific and multispecific antibodies, along with next-generation cancer vaccines. Presentations from vario...
Read More...
Nov 19, 2024
The 17th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, held in Madrid from October 29 to November 1, 2024, set the stage for groundbreaking updates in Alzheimer’s research, as pharmaceutical leaders presented their latest findings on novel therapies and cutting-edge clinical trials. With an ever-growing...
Read More...
Nov 20, 2024
Medical radiation detection devices are not just safety tools; they are integral to maintaining the delicate balance between leveraging the benefits of radiation and minimizing its risks. With radiation playing a pivotal role in diagnosing and treating life-threatening conditions such as cancer, the need for precis...
Read More...
Nov 19, 2024
FDA Approves AADC Deficiency Gene Therapy by PTC Therapeutics PTC Therapeutics, Inc. has secured FDA accelerated approval for KEBILIDI (eladocagene exuparvovec-tneq), marking a historic milestone as the first-ever gene therapy directly administered to the brain in the United States. This innovative therapy addre...
Read More...
Nov 22, 2024
NK cell therapies have demonstrated significant clinical efficacy, with studies reporting response rates ranging from 40% to 80% in certain hematologic malignancies. As of recent data, several NK cell therapy candidates are in clinical trials, with notable successes including improved overall survival rates and red...
Read More...
Nov 18, 2024
Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease. It affects about 10 million people worldwide. The average age of onset for Parkinson’s disease is around 60; however, approximately 10-15% of patients experience early-onset PD before the age of 50. In 2023, there...
Read More...